Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Wynn Resorts, Limited — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Wynn Resorts, Limited trades at $74 (market cap $7.79B). The key difference: Spyre Therapeutics Inc. Common Stock and Wynn Resorts, Limited are close in size by market cap, and Wynn Resorts, Limited pays a 1.32% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Wynn Resorts, Limited for 77 Days on average.
| SYRE | WYNN | |
|---|---|---|
Market Cap | $7.52B | $7.79B |
Volume | 1,441,031 | 1,551,566 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $133.09 |
52-Week Low | $22.18 | $73.73 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $6.52B | $18.04B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Wynn Resorts (WYNN) trades at $73.73, down 1.64% on the day, amid a bearish technical signal. The stock shows strong analyst support with a 64% buy rating and a consensus price target of $130.73, implying significant upside. Recent Q2 2026 earnings beat expectations, driven by Macau strength, though U.S. margins face pressure. The company maintains solid revenue growth, with 2026 revenue projected at $7.4B, but net cash flow remains negative due to high capital expenditures for expansion projects like Wynn Al Marjan.
The outlook for WYNN is cautiously optimistic, with Macau recovery and new project potential offering growth opportunities. However, risks include elevated debt levels, rising capex, and competitive pressures. Investors should weigh the substantial upside projected by analysts against execution risks and macroeconomic sensitivities affecting the gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
